title: [Effect of brown enriched Livex on the general condition of patients with proliferative diseases of the bone marrow and lymphatic system].
abstract: Brown Livex, a preparation of animal blood in doses of 5.0 g twice daily was given to 33 patients with proliferative diseases of bone marrow and lymphatic system during and after treatment with cytostatic agents. The course of treatment was 3 months. The effect of the preparation was studied on the wellbeing of the patients, body weight, general fitness (Karnofsky scale) and the levels of haemoglobin, haematocrit and beta-lipoproteins. The control groups comprised 20 patients with similar diseases and similar cytostatic treatment. In the studied group a positive effect was observed of the preparation on weight gain (26 out of 33 patients), well-being (24 of 33) and general fitness (17 of 33). In the control group during the same-time of observation weight loss was noted in 11 of 20 cases, well-being deterioration in 7 of 20, and decreased general fitness in 7 of 20. Livex treatment had no effect on haemoglobin level, haematocrit value, total serum protein, albumins and beta-lipoproteins.
authors.affiliation: Katedry i Kliniki Hematologii Ak. Med., Wrocławiu.
authors.forename: K
authors.initials: K
authors.lastname: Kuliczkowski
authors.forename: R
authors.initials: R
authors.lastname: Sciborski
authors.forename: M
authors.initials: M
authors.lastname: Kuliszkiewicz-Janus
authors.forename: Z
authors.initials: Z
authors.lastname: Gałazka
mesh_terms: D000328:Adult; D000368:Aged; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001769:Blood; D001798:Blood Proteins / Q000494:pharmacology*; D003131:Combined Modality Therapy; D004044:Dietary Proteins / Q000494:pharmacology*; D005260:Female; D006801:Humans; D008223:Lymphoma / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011379:Prognosis
chemical_list: D000970:Antineoplastic Agents; D001798:Blood Proteins; D004044:Dietary Proteins; C084915:Livex
vernacular_title: Wpływ Livexu brazowego wzbogaconego na stan ogólny chorych z chorobami rozrostowymi szpiku i układu chłonnego.